Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia

References

• Potaczek DP, Garn H, Unger SD, et al. Antisense molecules: a new class of drugs. J Allergy Clin Immunol. 2016;137:1334–1346. doi:10.1016/j.jaci.2015.12.1344.
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515. doi:10.1056/NEJMoa031766.
   PubMed Web of Science ®Google Scholar
• Blasi E, Bamberger M, Knight D, et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol. 2009;53:507–516.
   PubMed Web of Science ®Google Scholar
• Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150:2211–2219. doi:10.1210/en.2008-1512.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. doi:10.1056/NEJMoa0706628.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Hardman TC, Viljoen A. Inhibition of pro-protein convertase subtilisin kexin-9 (PCSK9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs. 2012;21:667–676.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Rungta P, Prasad AK. Nucleic acid therapeutics: basic concepts and recent developments. RSC Adv. 2014;4:16618. doi:10.1039/c3ra47841f.
   Web of Science ®Google Scholar
• Sharma VK, Watts JK. Oligonucleotide therapeutics: chemistry, delivery and clinical progress. Future Med Chem. 2015;7:2221–2242.
   PubMed Web of Science ®Google Scholar
• Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–284.
   PubMed Web of Science ®Google Scholar
• Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA. 1978;75:285–288.
   PubMed Web of Science ®Google Scholar
• Crooke RM, Graham MJ. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology. Methods Mol Biol. 2013;1027:309–324. doi:10.1007/978-1-60327-369-5_14.
   PubMedGoogle Scholar
• Pelka K, Shibata T, Miyake K, et al. Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology. Immunol Rev. 2016;269:60–75. doi:10.1111/imr.12375.
   PubMed Web of Science ®Google Scholar
• Engelhardt JA. Comparative renal toxicopathology of antisense oligonucleotides. Nucleic Acid Ther. 2016. doi:10.1089/nat.2015.0598.
   Google Scholar
• Ruda VM, Chandwani R, Sehgal A, et al. The roles of individual mammalian argonautes in RNA interference in vivo. PLoS One. 2014;9:e101749. doi:10.1371/journal.pone.0101749.
   Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi:10.1016/S0140-6736(10)61350-5.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–1884. doi:10.1016/S0140-6736(10)60656-3.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361. doi:10.1093/eurheartj/ehr112.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411–1416. doi:10.1016/j.jacc.2005.04.064.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K–34K. doi:10.1016/j.amjcard.2008.10.002.
   Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146–1156. doi:10.1016/j.jacc.2012.12.023.
   PubMed Web of Science ®Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–2475.
   PubMed Web of Science ®Google Scholar
• Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14:67–70. doi:10.1016/j.atherosclerosissup.2012.10.001.
   PubMed Web of Science ®Google Scholar
• Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet. 2015;54:133–146. doi:10.1007/s40262-014-0224-4.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Gunawan R, Li Z, et al. No effect on QT intervals of mipomersen, a 2ʹ-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Eur J Clin Pharmacol. 2016;72:267–275. doi:10.1007/s00228-015-1992-y.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Moon B, Hernandez-Ono A, et al. Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. Sci Transl Med. 2016;8:323ra12.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006. doi:10.1016/S0140-6736(10)60284-X.
   PubMed Web of Science ®Google Scholar
• Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650–2659. doi:10.1093/eurheartj/ehr148.
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36:566–575.
   PubMed Web of Science ®Google Scholar
• Santos RD, Raal FJ, Donovan JM, et al. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015;9:201–209. doi:10.1016/j.jacl.2014.12.008.
   PubMed Web of Science ®Google Scholar
• Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol. 2015;9:217–225.
   PubMed Web of Science ®Google Scholar
• Hashemi N, Odze RD, McGowan MP, et al. Liver histology during Mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol. 2014;8:606–611. doi:10.1016/j.jacl.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012;53:2515–2524. doi:10.1194/jlr.R026658.
   PubMed Web of Science ®Google Scholar
• van Poelgeest EP, Hodges MR, Moerland M, et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 2015;80:1350–1361.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60–68. doi:10.1016/S0140-6736(13)61914-5.
   PubMed Web of Science ®Google Scholar
• Maier MA, Jayaraman M, Matsuda S, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21:1570–1578. doi:10.1038/mt.2013.124.
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23:157–164. doi:10.1097/MED.0000000000000237.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339. doi:10.1001/jama.2009.801.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477. doi:10.1016/j.jacc.2013.09.038.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR. Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail. 2016;4:78–87. doi:10.1016/j.jchf.2015.08.006.
   PubMed Web of Science ®Google Scholar
• Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851–860. doi:10.1016/j.jacc.2014.03.061.
   PubMed Web of Science ®Google Scholar
• Parhofer KG. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des. 2011;17:871–876.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke RM, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57:340–351. doi:10.1194/jlr.R052258.
   PubMed Web of Science ®Google Scholar
• Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–699.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41. doi:10.1056/NEJMoa1308027.
   PubMed Web of Science ®Google Scholar
• Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2012;10:505–514.
   PubMedGoogle Scholar
• Furtado JD, Wedel MK, Sacks FM. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. J Lipid Res. 2012;53:784–791. doi:10.1194/jlr.P021717.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479–1490. doi:10.1161/CIRCRESAHA.111.300367.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438–447.
   PubMed Web of Science ®Google Scholar
• Yang X, Lee SR, Choi YS, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57:706–713. doi:10.1194/jlr.M066399.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200–2206.
   PubMed Web of Science ®Google Scholar
• Birch AM, Buckett LK, Turnbull AV. DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010;13:489–496.
   PubMedGoogle Scholar
• Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol. 2007;100:S53–S61. doi:10.1016/j.amjcard.2007.09.080.
   Google Scholar
• Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 2005;42:362–371. doi:10.1002/hep.20783.
   PubMed Web of Science ®Google Scholar
• Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282:22678–22688. doi:10.1074/jbc.M704213200.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–1374. doi:10.1002/hep.21655.
   PubMed Web of Science ®Google Scholar
• Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol (Lausanne). 2014;5:4.
   PubMed Web of Science ®Google Scholar
• Minicocci I, Tikka A, Poggiogalle E, et al. Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. J Lipid Res. 2016;57:1097–1107. doi:10.1194/jlr.P066183.
   PubMed Web of Science ®Google Scholar
• Brandt TA, Lee RG, Digenio A, et al. ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers. AtherosclerSuppl. 2015;241:e30–e31. doi:10.1016/j.atherosclerosis.2015.04.115.
   Google Scholar
• Wang Y, Gusarova V, Banfi S, et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56:1296–1307. doi:10.1194/jlr.M054882.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. J Clin Lipidol. 2016;10:715. doi:10.1016/j.jacl.2016.03.091.
   Google Scholar
• Norata GD, Sala F, Catapano AL, et al. MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Atherosclerosis. 2013;227:209–215. doi:10.1016/j.atherosclerosis.2012.11.019.
   PubMed Web of Science ®Google Scholar
• Karunakaran D, Rayner KJ. Macrophage miRNAs in atherosclerosis. Biochim Biophys Acta. 2016. doi:10.1016/j.bbalip.2016.02.006.
   PubMedGoogle Scholar
• Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 2013;57:533–542. doi:10.1002/hep.25846.
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404–407. doi:10.1038/nature10486.
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921–2931. doi:10.1172/JCI57275.
   PubMed Web of Science ®Google Scholar
• Ouimet M, Ediriweera HN, Gundra UM, et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest. 2015;125:4334–4348. doi:10.1172/JCI81676.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol. 2009;7:277–286.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther. 2013;13:7–10.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tang WH, Scoffone H, et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51:3055–3061. doi:10.1194/jlr.M008961.
   PubMed Web of Science ®Google Scholar
• Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–2576. doi:10.1161/CIRCULATIONAHA.113.002432.
   PubMed Web of Science ®Google Scholar